Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Melanotan II | Pentadeca Arginate (PDA) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 250-500 mcg daily via subcutaneous injection during loading, reducing to 250 mcg 2-3 times weekly for maintenance. | Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection. |
| Timing | Administer 4-6 hours before UV exposure for optimal tanning synergy. Can be taken at any time of day. | Administer on an empty stomach. Inject near site of injury for localized effect. |
| Cycle Duration | Loading phase 1-2 weeks, then maintenance as long as desired. Pigmentation fades gradually upon discontinuation. | 4-12 weeks depending on therapeutic target. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
Melanotan II is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that non-selectively agonizes melanocortin receptors MC1, MC3, MC4, and MC5. MC1R activation stimulates eumelanin synthesis through tyrosinase upregulation, producing tanning. MC3R activation in the CNS increases libido and produces erectile responses. MC4R activation suppresses appetite. The cyclic structure provides enhanced in vivo stability (half-life 1-2 hours) and increased blood-brain barrier permeability compared to linear alpha-MSH.
Research indicates 250-500 mcg daily via subcutaneous injection during loading, reducing to 250 mcg 2-3 times weekly for maintenance.
Administer 4-6 hours before UV exposure for optimal tanning synergy. Can be taken at any time of day.
Loading phase 1-2 weeks, then maintenance as long as desired. Pigmentation fades gradually upon discontinuation.
Pentadeca Arginate is a synthetic 15-amino acid peptide utilizing an arginate salt formulation of the BPC-157 sequence, designed to enhance nitric oxide production and promote angiogenesis. It stimulates collagen synthesis, enhances tissue repair through increased tensile strength, reduces inflammation via modulation of inflammatory cytokines, and accelerates cellular proliferation in tendon fibroblasts. The arginate salt form provides superior stability and bioavailability compared to traditional acetate formulations.
Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection.
Administer on an empty stomach. Inject near site of injury for localized effect.
4-12 weeks depending on therapeutic target.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →